Leerink Partners maintained an Outperform rating on Alexion Pharmaceuticals (NASDAQ: ALXN), and cut the price target to $216.00 (from $217.00). Conviction about the company is based on a positive outlook for Soliris [aHUS, PNH] and its potential in existing and new indications, as well as the potential of the company’s growing portfolio of other rare disease medicines generating incremental revenue.

Analyst Geoffrey Porges commented, "Today we are updating our Alexion model focusing on adjustments to marginal niche products, recent 10k disclosure, and updated currency effects; we reiterate our Outperform rating and trim our price target to $216."

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $127.91 yesterday.